CFDE Data Portal | Search GARRE1

	Label	Description
	GARRE1 Gene (Entity type)	ENSG00000166398 - granule associated Rac and RHOG effector 1
	GSE242555 1 V 0 NICOTINAMIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE213588 trametinib NF1 8 v 11 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE147662 3 V 1 NICOTINAMIDE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE139178 GDC-0068 3 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE111247 temozolomide LN-308 2 v 13 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE67266 7 V 3 ETOPOSIDE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE193993 SSTR2 knockout 4 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE218378 PBX1 overexpression HCT 116 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE230634 PARP inhibition 0 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS

GARRE1

ENSG00000166398 - granule associated Rac and RHOG effector 1

GSE242555 1 V 0 NICOTINAMIDE HUMAN DN

A Gene Set from LINCS

GSE213588 trametinib NF1 8 v 11 human up

A Gene Set from LINCS

GSE147662 3 V 1 NICOTINAMIDE MOUSE UP

A Gene Set from LINCS

GSE139178 GDC-0068 3 v 7 human up

A Gene Set from LINCS

GSE111247 temozolomide LN-308 2 v 13 human up

A Gene Set from LINCS

GSE67266 7 V 3 ETOPOSIDE MOUSE UP

A Gene Set from LINCS

GSE193993 SSTR2 knockout 4 v 7 human dn

A Gene Set from LINCS

GSE218378 PBX1 overexpression HCT 116 1 v 0 human up

A Gene Set from LINCS

GSE230634 PARP inhibition 0 v 4 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.